Cerqueti P M, Ricca V, Tosca M A, Buscaglia S, Ciprandi G
Eye Division, Ospedale Civile di Asti, Italy.
Int Arch Allergy Immunol. 1994 Oct;105(2):185-9. doi: 10.1159/000236823.
Lodoxamide is an antiallergic compound. The present study evaluated the efficacy on clinical and cytological parameters and safety of topical lodoxamide compared to placebo in the treatment of allergic conjunctivitis. The trial, designed as double-blind, randomized, placebo-controlled and parallel group treatment, was carried out in 30 patients, suffering from seasonal allergic conjunctivitis due to grass pollen, during the pollen season. Patients received lodoxamide tromethamine 0.1% eye drops or placebo eye drops, one drop in each eye t.i.d. for 4 weeks. The clinical and cytological evidence was investigated by clinicians on admission and after 4 weeks' treatment. At the end of the trial, only the lodoxamide-treated group showed a significant clinical improvement, associated with a reduction of inflammatory cells. No serious side effects were observed. The results show the clinical efficacy of lodoxamide in the treatment of pollen-induced allergic conjunctivitis. In addition, lodoxamide exerts its antiallergic activity by reducing inflammatory infiltrate (mainly eosinophils).
洛度沙胺是一种抗过敏化合物。本研究评估了局部使用洛度沙胺与安慰剂相比，在治疗过敏性结膜炎时对临床和细胞学参数的疗效及安全性。该试验设计为双盲、随机、安慰剂对照和平行组治疗，在花粉季节对30例因草花粉引起季节性过敏性结膜炎的患者进行。患者接受0.1%洛度沙胺 tromethamine 滴眼液或安慰剂滴眼液，每眼每日3次，每次1滴，共4周。临床医生在入院时和治疗4周后对临床和细胞学证据进行了调查。试验结束时，只有洛度沙胺治疗组显示出显著的临床改善，并伴有炎症细胞减少。未观察到严重副作用。结果表明洛度沙胺在治疗花粉诱导的过敏性结膜炎方面具有临床疗效。此外，洛度沙胺通过减少炎症浸润（主要是嗜酸性粒细胞）发挥其抗过敏活性。
